Eli Lilly's Immunology Push Builds New Growth Engines Beyond GLP-1s

Eli Lilly's immunology portfolio generated $2.6 billion in first-half 2026 revenue, up 9% year over year, led by Taltz at $1.6 billion; the franchise represented 6.1% of total company revenue. Lilly is expanding beyond GLP-1 drugs through its immunology pipeline and acquisitions, including the approximately $2.9 billion planned purchase of Merida Biosciences. Consensus 2026 EPS increased to $35.93 from $35.38 over 60 days, although Lilly trades at 26.18x forward earnings versus 18.02x for the industry and faces substantial competition across immunology indications.

Analysis

The investable issue is not near-term immunology revenue, but whether LLY can convert obesity cash flow into durable franchises before cardiometabolic growth normalizes. The acquired oral IL-17 and integrin assets create an option on payer-preferred, convenience-driven share capture in psoriasis and IBD, where oral agents can expand treated populations rather than merely displace injectable biologics. That strategic optionality supports a higher terminal-growth assumption over 6-18 months, but it is not yet large enough to offset a cardiometabolic miss in the next two quarters.

Competitive pressure is most relevant for ABBV and REGN/SNY. ABBV has the most direct exposure because successful oral IL-17 or alpha4beta7 programs could eventually erode the franchise durability assumed in Skyrizi/Rinvoq estimates; however, clinical, regulatory and launch execution put this risk beyond the 12-month horizon. REGN/SNY retain the stronger near-term atopic-dermatitis moat through Dupixent's breadth and established reimbursement, so Ebglyss uptake should be monitored as a rebate and formulary risk rather than modeled immediately as a major revenue transfer.

The contrarian view is that this news is insufficient for an outright LLY catalyst: early pipeline assets and acquisitions are likely already valued as broad strategic optionality, while repeated bolt-on deals increase capital-allocation scrutiny. Near term, the cleanest catalyst is evidence that newer products gain access without materially diluting net price; falsification is slower-than-expected new-start growth, elevated SG&A/rebate expense, or another acquisition that meaningfully raises the hurdle for incremental returns. LLY's valuation premium leaves it vulnerable to even modest downward revisions in the core franchise, despite improving longer-dated diversification.

Key Decisions for Investors

• Maintain LLY as a core long only if cardiometabolic prescription and supply indicators remain intact; add on post-earnings weakness rather than chase this pipeline narrative. Target a 6-18 month horizon; reduce if 2027 EPS consensus begins falling or management signals immunology-launch spending is pressuring operating-margin progression.
• Initiate a 12-18 month relative-value watch: long LLY versus short ABBV only after clinical updates or commercialization milestones validate oral immunology differentiation. The thesis requires evidence of meaningful IBD/psoriasis share capture; absent that, ABBV's current commercial assets and cash returns make the pair premature.
• Do not short REGN/SNY on Ebglyss alone. Set an alert for sequential Dupixent atopic-dermatitis growth deceleration combined with adverse formulary changes; that combination, rather than headline competition, would justify a 3-6 month tactical underweight.
• For downside protection on an existing LLY position, consider a 3-6 month put spread around the next earnings event, funded only partially with upside calls. The primary near-term risk remains a core-growth or gross-margin disappointment, not immunology clinical risk; size the hedge to earnings-gap exposure rather than the small current immunology revenue base.